Tilray (NASDAQ:TLRY) Trading Up 0.4% – Still a Buy?

Shares of Tilray Inc (NASDAQ:TLRY) traded up 0.4% during mid-day trading on Tuesday . The company traded as high as $1.25 and last traded at $1.21. 10,968,820 shares were traded during mid-day trading, a decline of 57% from the average session volume of 25,766,971 shares. The stock had previously closed at $1.20.

Wall Street Analyst Weigh In

Separately, Roth Mkm lowered their price objective on Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a research report on Friday, October 11th.

Tilray Trading Up 2.1 %

The business’s 50-day moving average is $1.47 and its two-hundred day moving average is $1.67. The stock has a market capitalization of $1.11 billion, a PE ratio of -4.50 and a beta of 2.08. The company has a quick ratio of 1.57, a current ratio of 2.47 and a debt-to-equity ratio of 0.08.

Tilray (NASDAQ:TLRY) last released its quarterly earnings results on Thursday, October 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). The firm had revenue of $200.00 million for the quarter, compared to the consensus estimate of $218.70 million. Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.10) EPS. On average, analysts anticipate that Tilray Inc will post -0.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Tilray

In other news, CFO Carl A. Merton acquired 26,000 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were purchased at an average cost of $1.36 per share, for a total transaction of $35,360.00. Following the transaction, the chief financial officer now directly owns 26,000 shares in the company, valued at approximately $35,360. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 0.87% of the stock is currently owned by company insiders.

Institutional Trading of Tilray

Several hedge funds and other institutional investors have recently made changes to their positions in TLRY. Synovus Financial Corp increased its position in Tilray by 176.7% during the 3rd quarter. Synovus Financial Corp now owns 36,092 shares of the company’s stock worth $64,000 after purchasing an additional 23,046 shares during the period. Barclays PLC lifted its holdings in Tilray by 600.4% in the third quarter. Barclays PLC now owns 204,144 shares of the company’s stock valued at $359,000 after acquiring an additional 174,997 shares during the period. Toronto Dominion Bank boosted its position in shares of Tilray by 454.5% during the 3rd quarter. Toronto Dominion Bank now owns 128,923 shares of the company’s stock worth $227,000 after purchasing an additional 105,671 shares in the last quarter. XTX Topco Ltd grew its stake in shares of Tilray by 1,079.7% during the 3rd quarter. XTX Topco Ltd now owns 281,504 shares of the company’s stock worth $495,000 after purchasing an additional 257,641 shares during the period. Finally, State Street Corp boosted its holdings in Tilray by 4.7% during the third quarter. State Street Corp now owns 1,961,338 shares of the company’s stock worth $3,452,000 after buying an additional 88,079 shares in the last quarter. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.